| Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human … KC Conlon, E Lugli, HC Welles, SA Rosenberg, AT Fojo, JC Morris, ... Journal of clinical oncology 33 (1), 74-82, 2015 | 719 | 2015 |
| Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma RL Piekarz, R Frye, HM Prince, MH Kirschbaum, J Zain, SL Allen, ES Jaffe, ... Blood, The Journal of the American Society of Hematology 117 (22), 5827-5834, 2011 | 541 | 2011 |
| Selumetinib in children with inoperable plexiform neurofibromas AM Gross, PL Wolters, E Dombi, A Baldwin, P Whitcomb, MJ Fisher, ... New England Journal of Medicine 382 (15), 1430-1442, 2020 | 512 | 2020 |
| Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma N Korde, M Roschewski, A Zingone, M Kwok, EE Manasanch, M Bhutani, ... JAMA oncology 1 (6), 746-754, 2015 | 336 | 2015 |
| Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors C Grant, F Rahman, R Piekarz, C Peer, R Frye, RW Robey, ER Gardner, ... Expert review of anticancer therapy 10 (7), 997-1008, 2010 | 285 | 2010 |
| Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial … JM Lee, A Cimino-Mathews, CJ Peer, A Zimmer, S Lipkowitz, ... Journal of Clinical Oncology 35 (19), 2193-2202, 2017 | 255 | 2017 |
| The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response JP Lewis, RB Horenstein, K Ryan, JR O’Connell, Q Gibson, BD Mitchell, ... Pharmacogenetics and genomics 23 (1), 1-8, 2013 | 177 | 2013 |
| Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer RZ Szmulewitz, CJ Peer, A Ibraheem, E Martinez, MF Kozloff, B Carthon, ... Journal of Clinical Oncology 36 (14), 1389-1395, 2018 | 173 | 2018 |
| Diabetic cardiomyopathy-associated dysfunction in spatially distinct mitochondrial subpopulations ER Dabkowski, CL Williamson, VC Bukowski, RS Chapman, SS Leonard, ... American Journal of Physiology-Heart and Circulatory Physiology 296 (2 …, 2009 | 166 | 2009 |
| Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress A Thomas, N Takahashi, VN Rajapakse, X Zhang, Y Sun, M Ceribelli, ... Cancer Cell 39 (4), 566-579. e7, 2021 | 133 | 2021 |
| Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia CJ Peer, TM Sissung, AR Kim, L Jain, S Woo, ER Gardner, CT Kirkland, ... Clinical cancer research 18 (7), 2099-2107, 2012 | 131 | 2012 |
| IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion KC Conlon, EL Potter, S Pittaluga, CCR Lee, MD Miljkovic, TA Fleisher, ... Clinical Cancer Research 25 (16), 4945-4954, 2019 | 115 | 2019 |
| Pomalidomide for symptomatic Kaposi's sarcoma in people with and without HIV infection: a phase I/II study MN Polizzotto, TS Uldrick, KM Wyvill, K Aleman, CJ Peer, M Bevans, ... Journal of Clinical Oncology 34 (34), 4125-4131, 2016 | 115 | 2016 |
| Reactive astrocytic S1P3 signaling modulates the blood–tumor barrier in brain metastases B Gril, AN Paranjape, S Woditschka, E Hua, EL Dolan, J Hanson, X Wu, ... Nature communications 9 (1), 2705, 2018 | 107 | 2018 |
| A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study A Thomas, A Rajan, E Szabo, Y Tomita, CA Carter, B Scepura, ... Clinical Cancer Research 20 (21), 5392-5402, 2014 | 107 | 2014 |
| The CYP2C19* 17 variant is not independently associated with clopidogrel response JP Lewis, SH Stephens, RB Horenstein, JR O'Connell, K Ryan, CJ Peer, ... Journal of Thrombosis and Haemostasis 11 (9), 1640-1646, 2013 | 103 | 2013 |
| A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with … AS Zimmer, E Nichols, A Cimino-Mathews, C Peer, L Cao, MJ Lee, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 99 | 2019 |
| Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or‐refractory epithelial ovarian cancer AM Noonan, KP Bunch, JQ Chen, MA Herrmann, JM Lee, EC Kohn, ... Cancer 122 (4), 588-597, 2016 | 93 | 2016 |
| An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer MS Gordon, F Robert, D Matei, DS Mendelson, JW Goldman, ... Clinical cancer research 20 (23), 5918-5926, 2014 | 88 | 2014 |
| Phase I and preliminary phase II study of TRC105 in combination with sorafenib in hepatocellular carcinoma AG Duffy, C Ma, SV Ulahannan, OE Rahma, O Makarova-Rusher, L Cao, ... Clinical Cancer Research 23 (16), 4633-4641, 2017 | 86 | 2017 |
